Pharmaceutical - Novo Nordisk, AstraZeneca, Healthcare


EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs


Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

Briefs: New research deals for AstraZeneca and Novo Nordisk; Lundbeck's Selincro launched in Europe


Anglo-Swedish drug major AstraZeneca and BIND Therapeutics, a US clinical-stage biopharmaceutical, have…

AstraZenecaBIND TherapeuticsBiotie TherapiesEuropeKymabLundbeckMarkets & MarketingNovo NordiskOncologyPharmaceuticalResearchSelincro

Novo Nordisk and AstraZeneca among firms to invest in Russian pharma hub


In Russia, the Kaluga government plans to establish a pharmaceutical manufacturing hub in the region…

AstraZenecaEuropeFinancialMarkets & MarketingMenariniNovo NordiskPharmaceuticalSTADA Arzneimittel

AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza


Anglo-Swedish drug major AstraZeneca ILSE: AZN) said this morning that it is investing $200 million in…

Asia-PacificAstraZenecaDiabetesFinancialMarkets & MarketingNovo NordiskPharmaceuticalRegulationVictoza

Approval of diabetes drugs from AstraZeneca/B-MS and Novo Nordisk supported by EU’s CHMP; Faslodex cleared in Japan


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued…

Asia-PacificAstraZenecaBristol-Myers SquibbDiabetesEuropeFaslodexKomboglyzeLevemirNovo NordiskOncologyPharmaceuticalRegulationsaxagliptinVictoza

Back to top